-
Electronic (PDF)
-
Site License
-
Enterprisewide
Metastatic Pancreatic Cancer - Pipeline Review, Q1 2011
Global Markets Direct, January 2011, Pages: 96
Metastatic Pancreatic Cancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Metastatic Pancreatic Cancer - Pipeline Review, Q1 2011', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Metastatic Pancreatic Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Pancreatic Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer Therapeutics under Development by Companies
Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development
Bristol-Myers Squibb Company
Abraxis BioScience, Inc.
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Infinity Pharmaceuticals, Inc.
NeoPharm, Inc.
YM BioSciences Inc.
MediGene AG
Astellas Pharma Inc.
Celgene Corporation
Bayer AG
Oncolytics Biotech Inc.
NanoCarrier Co., Ltd.
Rexahn Pharmaceuticals, Inc.
Colby Pharmaceutical Company
Wellstat Therapeutics Corporation
Oncoscience AG
MacroGenics, Inc.
Immutep S.A.
AmpliMed Corporation
AB Science
Theradex Systems, Inc.
Universities/Institutes Involved in Metastatic Pancreatic Cancer Therapeutics Development
Metastatic Pancreatic Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AB1010 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane + Gemzar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Gemcitabine_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vistonuridine + 5-fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Bevacizumab + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Gemcitabine + Erlotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erlotinib hydrochloride + gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine + Vaccine GV1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine + Vaccine therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Dalteparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Metastatic Pancreatic Cancer - Featured News
Sep 02, 2010: Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Agensys
Jul 20, 2010: Seattle Genetics And Agensys Initiate Phase I Clinical Trial Of ASG-5ME For Metastatic Pancreatic Cancer
Jun 07, 2010: Clivatuzumab Tetraxetan Shows Promising Results In Patients With Metastatic Pancreatic Cancer
Jun 07, 2010: Immunomedics Reports Updated Results Of Targeted Therapy For Advanced Pancreatic Cancer
May 24, 2010: Epeius To Present Phase I/II Study Results Of Rexin-G For Treatment Of Gemcitabine-Resistant Metastatic Pancreas Cancer At ASCO 2010
Apr 20, 2010: NeoPharm Initiates Patient Enrollment In Phase II Trial Of LE-DT
Apr 18, 2010: ABRAXANE(R) In Combination With Gemcitabine Increases Survival In First-Line Treatment of Advanced Pancreatic Cancer In Phase I/II Study.
Mar 14, 2008: Raven Announces Initiation Of A RAV12 Phase 2 Clinical Trial In Metastatic Pancreatic Cancer
Jul 13, 2007: Rigel Announces Start Of Phase 1 Combination Therapy Study Of R763/AS703569 In Advanced Malignancies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Metastatic Pancreatic Cancer, 2011
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Abraxis BioScience, Inc., 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
Eli Lilly and Company, 2011
Daiichi Sankyo Company, Ltd, 2011
Infinity Pharmaceuticals, Inc., 2011
NeoPharm, Inc., 2011
YM BioSciences Inc., 2011
MediGene AG, 2011
Astellas Pharma Inc., 2011
Celgene Corporation, 2011
Bayer AG, 2011
Oncolytics Biotech Inc., 2011
NanoCarrier Co., Ltd., 2011
Rexahn Pharmaceuticals, Inc., 2011
Colby Pharmaceutical Company, 2011
Wellstat Therapeutics Corporation, 2011
Oncoscience AG, 2011
MacroGenics, Inc., 2011
Immutep S.A., 2011
AmpliMed Corporation, 2011
AB Science, 2011
Theradex Systems, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, 2011
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
